Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

Leukemia and Lymphoma

Volumn 31, Issue 5-6, 1998, Pages 521-531

  Beran, Miloslav ^a   Estey, Elihu ^a   O'Brien, Susan M ^a   Giles, Francis J ^a   Koller, Charles A ^a   Kornblau, Steven ^a   Keating, Michael ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelomonocytic leukemia; Myelodysplastic syndrome; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; FOLLOW UP; GENE MUTATION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; MONOCYTE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ONCOGENE H RAS; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032465406     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057611     Document Type: Article

References (45)

1. Beran, M. (1991) Treatment of myelodysplastic syndromes. In Therapy of Hematopoietic Neoplasia, edited by E Freireich and H Kantarjian, pp. 35-82. New York. Dekker.
2. Bennett, J.M. (1986) Classification of the myelodysplastic syndromes. Clinical Haematology, 15, 909-923.
3. Aul, C., Gattermann, N., Germing, U., Runde, V., Heyll, A. and Schneider, W. (1994) Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia, 8, 1906-1913.
4. Morel, P., Hebbar, K., Lai, J-L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. and Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system. A report on 408 cases. Leukemia, 7, 1315-1324.
5. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Gaiton, D., Gralnick, H., Sultan, C. and Cox, C. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. British Journal of Haematology, 87, 746-754.
6. Michaux, J.L., and Martiat, P. (1993) Chronic myelomonocytic leukaemia (CMML): a myelodysplastic or myeloproliferative syndrome? Leukemia and Lymphoma, 9, 3-5.
7. Kantarjian, H.M., Keating, M.J., Walters, R.S., McCredie, K.B., Smith, T.L., Talpaz, M., Beran, M., Cork, A., Trujillo, J.K. and Freireich, E.J (1986) Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer, 58, 2023-2030.
8. Giles, F.J., Hamon, M.D. and Newland, A.C. (1988) Transient response to alpha-2b-interferon in patients with myelodysplasia [abstract]. British Journal of Haematology, 69, 123.
9. Koeffler, B.P., Heitlan, D., Mertelsmann, R., Kolitz, J.E., Schulman, P., Itri, L., Gunter, P. and Besa, E. (1987) Randomized study of 13-cis-retin acid versus placebo in the myelodysplastic disorders. Blood. 71, 703-708.
10. Clark, R.E., Ismail, S.A.D., Jacobs, A. and West, R.R. (1987) A randomized trial of13-cis-retinoic acid with or without cytosine arabinoside in patients with myelodysplastic syndrome British Journal of Haematology, 66, 77-83.
11. Arcenas, A.G. and Vadhan-Raj, S. (1993) Hematopoietic growth factor therapy of myelodysplastic syndromes. Leukemia and Lymphoma, 11, 65-69.
12. Gerhartz, H.H., Marcus, R., Delmer, A., Zwierzina, H., Suciu, S., Dardenne, M., Solbu, G., deWitte, T., Jacobs, A. and Visani, G. (1994) A randomized phase II study of low-dose cytosine arabinoside (LD-Ara-C) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia, 8, 16-23.
13. Cheson, B.D., Jasperse, D.M., Simon, R. and Friedman, M.A. (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology, 4, 1857-1864.
14. Greenberg, B.R., Reynolds, R., Charron, C.B., Squillace, K.M., Lessin, L.S., Case, D.C. and Gams, R.A. (1993) Treatment of myelodysplastic syndromes with daily oral Idarubicin. Cancer, 71, 1989-1992.
15. Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P. and Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology 77, 497-501.
16. Estey, E., Pierce, S., Kantarjian, H., O'Brien, S., Beran, M., Andreeff, M., Escudier, S., Koller, C., Kornblau, S., Robertson, L. and Keating, M. (1993) Treatment ofmyelodysplastic syndromes with AML-type chemotherapy. Leukemia and Lymphoma 11 (Suppl I), 59-63.
17. [17) DeWitte, T., Zwaan, F., Hermans, H., Vernant, J., Kolb, H., Vossen, J., Lonnqvist, B., Beelen, D., Ferrant, A. and Gmur, J. (1989) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Bone Marrow Transplantation 4 (Suppl 3), 38-39.
18. Anderson, J.E., Appelbaum, F., Schoch, G., Gooley, T., Anasetti , C., Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T., Clift, R.A., Decg, H.J., Doney, K., Flowers, M., Hansen J.A., Martin, P.J., Matthews, D.C., Nash, R.A., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P. and Storb, R. (1996) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study ofbusulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. Journal of Clinical Oncology 14, 220-226.
19. Liu, L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 58, 351-375.
20. Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W, Liu, L.F., Silber, R. and Potsmeil, M. (1989) DNA topoisomerase target chemotherapy of human colon cancer xenografts. Science 246, 1046-1048.
21. Fukuoka., M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S. and Masuda, N. (1992) A phase II study of CTP-1 1, a new derivative of camptothecin for previously untreated non-small cell lung cancer. Journal of Clinical Oncology 10, 16-20.
22. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T. and Ogawa, N. (1991) Phase II study of CPT-11 a new camptothecin derivative, in patients with metastatic colorectal cancer [abstract]. Proceedings of the American Society of Clinical Oncology 10, 909-913.
23. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y. and Oguro, M. (1990) An early phase II study of CPT-11 a new derivative of camptothecin for the treatment of leukemia and lymphoma. Journal of Clinical Oncology 8, 1907-1912.
24. Kantarjian, H.M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M.B., Plunkett, W., Keating, M.J., and Estey, E.H. (1993) Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed leukemia. Blood 81, 1146-1151.
25. Rowinsky, E.K., Adjei, A., Donehower, R.C., Gore, S.D., Jones R.J., Burke, P.J., Cheng, Y-C., Gorchow, L.B., and Kaufmann, S.H. (1994) Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology 12, 2193-2203.
26. Estey, E., Keating, M.J., Dixon, D., Trujillo, J.M., McCredie, K.B., and Freireich, E. (1987) Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic myelogenous leukemia. Hematological Pathology 1, 203-208.
27. Beran, M., Kantarjian, H., O'Brien, S., Koller, C., Albitar, M., Arbuck, S., Pierce, S., Moore, M., Abbruzzese, J., Andreeff, M., Keating, M. and Estey, E. (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88, 2473-2479.
28. Trujillo, J.M., Cork, A. and Ahearn, M.J. (1979) Hematologic and cytologic characteristics of 8;21 translocation acute granulocytic leukemia. Blood 53, 695-706.
29. LeMaistre, A., Lee, M.S., Talpaz, M., Kantarjian, H.M., Freireich, E.J, Deisseroth, A.B., Trujillo, J.K. and Stass, R.A. (1989) RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 73, 889-891.
30. Nakagawa, T., Saitoh, S., Imoto, S., Itoh, M., Tsutsumi, M., Hikiji, K., Nakamura, H., Matozaki, S., Ogawa, R. and Nakao, Y. (1992) Multiple point mutations ofN-ras and K-ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 49, 114-122.
31. Erlich, H., Bugawan, T., Begovich, A.B., Scharf, S., Griffith, R., Saiki, R., Higuchi, R. and Walsh, P.S. (1991) HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. European Journal of Immunogenetics 18, 33-55.
32. Cai, S.P., Wall, J., Kan, Y.W., and Chehab, Y.W. (1994) Reverse dot blot probes for the screening of beta-thalassemia mutations in Asians and American blacks. Human Mutation Journal 3, 59-63.
33. Cuppens, H., Marynen, P., De Boeck, C. and Cassiman, J.J. (1993) Detection of 98.5% of the mutations in 200 Belgian cystic fibrosis alleles by reverse dot-blot and sequencing of the complete coding region and exon-intron junctions ofthe CFTR gene. Genomics 18, 693-697.
34. Silverman, L., Holland, J., Weinberg, R., Alter, B., Davis, B., Ellison, R., Demakos, E., Cornell, C., Carey, R., Schiffer, C., Frei, E. and McIntyre, O.R. (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7, 21-29.
35. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Institute, 1988.
36. Gehan, E. (1961) The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 13, 346-353.
37. Kaplan, E.L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association 53, 457-482.
38. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Report 50, 163-170.
39. Raza, A., Gezer, S., Mundle, S., Gao, X-Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S. and Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86, 268-276.
40. Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. and Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89, 3323-3329.
41. Pinto, A. and Zagonel, V. (1993) 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present, and future trends. Leukemia 7, 51-60.
42. Anzai, H., Frost, P. and Abbruzzese, J.L. (1992) Synergistic cytotoxicity with 2′-deoxy-5- and topotecan in vitro and in vivo. Cancer Research 52, 2180-2185.
43. Cogswell, P.C., Morgan, R., Dunn, M., Neubauer, A., Nelson, P., Polland-Johnston, N.K., Sandberg, A.A. and Liu, E. (1989) Mutations of the RAS proto-oncogenes in chronic myelogenous leukemias: a high frequency of RAS mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 74, 2629-2633.
44. Ginsberg, C.H., LeMaistre, A.C., Kantarjian, H., Talpaz, M., Cork, A., Freireich, E., Trujillo, J.M., Lee, M-S. and Stass, S.A. (1990) RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76, 1214-1219.
45. Seiter, K., Feldman, E.J., Halicka, D., Trananos, F., Zbigniew, D., Lake, D. and Ahmed, T. (1997) Phase I clinical and laboratory evaluation oftopotecan and cytarabine in patients with acute leukemia. Journal of Clinical Oncology 15, 44-51.